AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
$4.5M raised in self-underwritten public offering by BioSante.(Brief Article)
2002 NOV 6 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BISP) announced that it has raised $4,500,000 in a self-underwritten, best efforts public offering under a registration statement filed with the Securities and Exchange Commission.
Proceeds of the offering will be used to fund human clinical trials of BioSante's hormone replacement gel products, continue development of its proprietary calcium phosphate nanoparticles (CAP) as a vaccine adjuvant and drug delivery system, and for working capital and other general corporate purposes.
"These proceeds will allow us to aggressively pursue the clinical development of our hormone replacement products on schedule and according to plan," said Stephen M. Simes, president and chief executive officer of BioSante. "The environment for raising funds in the current equity market is as difficult as we have ever seen it. In approving this offering, our board of directors balanced the need to continue to aggressively fund product development against potential stockholder ...
- BioSante Pharmaceuticals Receives Milestone Payment and Reports Third Quarter...
- Press release article from: PR Newswire November 14, 2002 700+ words
...clinical development of BioSante's hormone therapy product...In September 2002, BioSante raised $4,500,000 in a self- underwritten public offering. These proceeds are...ongoing development of BioSante's products over the...
- Milestone payment received, 3Q performance reported.(BioSante Pharmaceuticals...
- Magazine article from: Women's Health Weekly December 26, 2002 700+ words
...clinical development of BioSante's hormone therapy product...In September 2002, BioSante raised $4,500,000 in a self-underwritten public offering. These proceeds are...ongoing development of BioSante's products over the...
- BioSante receives Solvay milestone.
- Newspaper article from: Pharma Marketletter November 25, 2002 700+ words
BioSante Pharmaceuticals of the USA has received a clinical milestone payment...September, the firm raised $4.5 million in a self-underwritten public offering, and this is expected to support its ongoing development program for...
- BioSante Pharmaceuticals Reports Second Quarter 2009 Financial...
- Press release article from: Business Wire August 7, 2009 700+ words
LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (NASDAQ...second quarter 2009 financial results. BioSante incurred a net loss of approximately...This decrease in net loss was due to BioSante's decision in April 2009 to delay...
- BioSante Pharmaceuticals Announces Management Changes.
- Press release article from: Business Wire December 2, 2005 700+ words
LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that BioSante has engaged Michael C. Snabes, M.D...as an independent consultant to work with BioSante's current product development team in...
- BioSante Pharmaceuticals Closes $12 Million Registered Direct Offering.
- Press release article from: Business Wire August 14, 2009 700+ words
LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (NASDAQ...aggregate of 6,000,000 shares of BioSante's common stock and warrants to purchase...resulting in gross cash proceeds to BioSante of approximately $12.0 million...
- BioSante Licenses Portfolio of Innovative Hormone Replacement Therapies to...
- Press release article from: PR Newswire September 5, 2000 700+ words
...MONTREAL, Sept. 5 /PRNewswire/ - BioSante Pharmaceuticals, Inc. (OTCBB:BTPH...agreement whereby Paladin will sub-license BioSante's portfolio of female hormone replacement...in Canada. "This agreement provides BioSante a strong partner with proven expertise...
- BioSante Pharmaceuticals Reports LibiGel[R] Status and Financial Results for...
- Press release article from: Business Wire March 16, 2009 700+ words
LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (NASDAQ...year ended December 31, 2008. "BioSante had an excellent year in 2008. Our...trials," said Stephen M. Simes, BioSante's president and chief executive...
Source: HighBeam Research, $4.5M raised in self-underwritten public offering by BioSante.(Brief...